Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology | Immunology
Clinical Trials: Lymphoma
A listing of clinical trials currently looking for volunteers to enroll in Lymphoma studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Muscle Shoals : Northwest Alabama Cancer Center
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Birmingham : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Birmingham : University of Alabama at Birmingham
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Birmingham : University of Alabama at Birmingham
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Birmingham :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Birmingham : Achieve Clinical Research, LLC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Birmingham : University of Alabama at Birmingham
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Huntsville : Clearview Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Huntsville : Clearview Cancer Institute
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Huntsville : TG Therapeutics Investigational Trial Site
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Huntsville : Clearview Cancer Institute
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Huntsville : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Huntsville : TG Therapeutics Investigational Trial Site
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Tuscaloosa : DCH Cancer Treatment Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Arizona
Casa Grande : Cancer Treatment Services Arizona
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Chandler : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Chandler : Ironwood Cancer and Research Centers Ironwood
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phoenix : Phoenix Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Scottsdale : Scottsdale Healthcare, Site #134
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
View More »
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Scottsdale : Mayo Clinic in Arizona
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Scottsdale : TGen Clinical Research Services at Scottsdale Healthcare
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Tucson : Arizona Oncology Associates, PC - HOPE
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Tucson : Arizona Clinical Research Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Tucson : Arizona Oncology Associates
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Tucson : Arizona Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Tucson : University of Arizona (SPORE)
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Tucson : The University of Arizona Cancer Center
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Tucson : Arizona Cancer Center
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Tucson : U Arizona Cancer Center
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Tucson : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Arkansas
Bentonville : Highlands Oncology Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Fayetteville : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Fayetteville : Highlands Oncology Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Hot Springs : Investigational Site Number 840018
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
View More »
Hot Springs : Genesis Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Little Rock : University of Arkansas for Medical Sciences
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Little Rock : University of Arkansas for Medical Sciences
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Little Rock : The University of Arkansas for Medical Sciences
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Rogers : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
California
Beverly Hills : Tower Cancer Research Foundation
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.
Burbank : Providence Saint Joseph Medical Center
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Duarte : City of Hope
BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
Duarte : City of Hope
Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial
Duarte : City of Hope
Prevalence and Biomarkers of Cardiac Left Ventricular Dysfunction in Lymphoma Survivors and Healthy Controls
Fountain Valley : St. Joseph Mercy Hospital
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
La Jolla : Moores UCSD Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Loma Linda : Loma Linda U Cancer Center
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Rancho Mirage : Desert Hematology Oncology Medical Group
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Santa Maria : Central Coast Medical Oncology Corp.
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Stanford : Stanford University School of Medicine
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Sunnyvale : Pharmacyclics
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Berkeley : Alta Bates Summit Medical Center-Herrick
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Berkley : Sutter East Bay Hospitals
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Beverly Hills : Tower Cancer Research Center
A Study of MLN9708 in Adult Patients With Lymphoma
Beverly Hills : Providence Health Services
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Beverly Hills : Tower Cancer Research Foundation
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Beverly Hills : Tower Cancer Research Foundation
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Burbank : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Burbank : Providence St Joseph Medical Center
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Burbank : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Burbank : Providence Saint Joseph Medical Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Burbank : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Burbank : Providence Saint Joseph Medical Center
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Burbank : Roy and Patricia Disney Family Cancer Center
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Corona : Compassionate Cancer Care Medical Group, Inc.
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Corona : Compassionate Cancer Care Medical Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Duarte : City of Hope National Medical Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Duarte : City of Hope Hospital
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Duarte : City of Hope National Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Duarte : City of Hope National Medical Center
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Duarte : City of Hope National Medical Center
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Duarte : City of Hope
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Duarte : City of Hope Comprehensive Cancer Center
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Fountain Valley : Compassionate Cancer Care Medical Group, Inc.
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Fountain Valley : Lalita Pandit, MD Inc.
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Fountain Valley : Compassionate Cancer Care Medical Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Fountain Valley : Fountain Valley Regional Hospital
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Fresno : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Fresno : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Fullerton : St. Jude Heritage Medical Group
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Fullerton : St. Jude Heritage Healthcare
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Greenbrae : Sutter Health Cancer Research Group California Cancer Care
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Greenbrae : California Cancer Care
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Huntington Beach : Pacific Shores Medical Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
La Jolla : Site Reference ID/Investigator# 48325
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
La Jolla : Site Reference ID/Investigator# 70398
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
La Jolla : Moores UCSD Cancer Center
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
La Jolla : Moores UCSD Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
La Jolla : Moores Cancer Center UCSD
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
La Jolla : Moores Ucsd Cancer Center
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
La Jolla : University of California San Diego Dept of Moores Cancer Ctr (3)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
La Jolla : Moores University of California San Diego Cancer Center
Safety and PK Study of RRx-001 in Cancer Subjects
La Jolla : University of California, San Diego
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
La Jolla : Moores Cancer Center- UCSD
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
La Verne : Wilshire Oncology Medical Group
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Lancaster : Antelope Valley Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Loma Linda : Loma Linda University Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Long Beach : Pacific Shores Medical Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Long Beach : Miller Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Los Alamitos : Pacific Shores Medical Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Los Angeles : Site Reference ID/Investigator# 67343
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Los Angeles : Children's Hospital of Los Angeles
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Los Angeles : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Los Angeles : Investigational Site Number 840012
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Los Angeles :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Los Angeles : Childrens Hospital Los Angeles
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Los Angeles :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Los Angeles : Childrens Hospital Los Angeles
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Los Angeles : UCLA
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Los Angeles : Santa Monica Hematology/Oncology
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Los Angeles : UCLA
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Los Angeles : USC & Norris Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Los Angeles : Ucla-Division Of Hematology/Oncology
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Los Angeles : Cedars-Sinai Medical Center
KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Los Angeles : USC/Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisMedicalCenter(4)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Los Angeles : Division Of Hematology & Oncology Ctr. For Health Sciences
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Los Angeles : Cedars-Sinai Medical Center-Samuel Oschin Comprehensive Cancer Institute
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Los Angeles : UCLA Neuro-Oncology Program
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Los Angeles : Jonsson Comprehensive Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Los Angeles : TORI- Central Pharmacy
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Los Angeles : TORI- Central Regulatory
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Los Angeles : University of Southern California
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Los Angeles : UCLA
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Los Angeles : Childrens Hospital Los Angeles
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Monterey : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Oakland : Oakland Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Orange : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Orange : Medical Oncology Care Associates
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Orange : University of California - Irvine
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Orange County : Children's Hospital of Orange County
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Oxnard : Ventura County Hematology Oncology Specialists
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Oxnard : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Palm Springs : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Palm Springs : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Palo Alto : Stanford Medical Center
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Palo Alto : Stanford Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Palo Alto : Stanford Cancer Center
Safety and Efficacy Study of CAL-101 in Patients With Previously Treated Low-grade Lymphoma
Palo Alto : Stanford Cancer Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Palo Alto : Stanford University Medical Center
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Pasadena : City of Hope Medical Group
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Pleasant Hill : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Pleasant Hill : Bay Area Cancer Research Group
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Rancho Cucamonga : Wilshire Oncology Medical Group
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Rancho Mirage : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Sacramento : Radiology Associates of Sacramento
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Sacramento : University of California Davis Cancer Center
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Sacramento : University of California Davis Cancer Center
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Sacramento : University of California - Davis
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
San Diego : University of California, San Diego: Moores Cancer Center, Site #099
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
San Diego :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
San Diego : Moores UCSD Cancer Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
San Diego : San Diego Pacific Oncology & Hematology Assoc Inc.
Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma
San Diego : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
San Diego : Sharp Healthcare
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
San Diego : Sharp Memorial Hospital
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
San Diego : University of California, San Diego
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
San Francisco : University of California, San Francisco
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center
Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
San Francisco : University of California at San Francisco
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
San Francisco : University of California at San Francisco
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
San Francisco : UCSF School of Medicine
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
San Francisco : University of California, San Francisco
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Santa Barbara : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Santa Maria : Central Coast Medical Oncology Corp.
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Santa Maria : Central Coast Medical Oncology Corporation
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Santa Monica : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Santa Monica : UCLA Hematology-Oncology Santa Monica
Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Santa Rosa : Redwood Regional Medical Group, Inc.
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Stanford : Stanford University School of Medicine
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Stanford : Stanford Cancer Center
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Stanford : Stanford University School of Medicine
A Phase II Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Stanford : Stanford Cancer Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Stanford : Stanford Cancer Center - Stanford University
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Stanford :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Stanford : Pfizer Investigational Site
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Stanford :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Stanford :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Stanford : Stanford University School of Medicine
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Stanford : Stanford University
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Stanford : Stanford University Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Stanford : Stanford University School of Medicine
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Stanford : Stanford University School of Medicine
Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Stanford : Stanford University School of Medicine
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Stanford : Stanford University School of Medicine
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Stanford : Stanford University
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Stanford : Stanford Medical Center
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Stanford : Stanford University School of Medicine
TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas
Sylmar : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sylmar : UCLA Olive View Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Colorado
Denver : Rocky Mountain Cancer Centers
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.
View More »
Aurora : University of Colorado Colorado Univ
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Aurora : University of Colorado Hospital, Site #015
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Aurora : Children's Hospital
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Aurora : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Aurora :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Aurora : Rocky Mountain Cancer Centers
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Aurora : University of Colorado Cancer Center
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Aurora : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Aurora : Investigational Site Number 840004
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Aurora : Children's Hospital Colorado
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Boulder : Rocky Mountain Cancer Centers
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Colorado Springs : Memorial Hospital
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Colorado Springs : Memorial Cancer Medicine Specialists
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Denver : Colorado Blood Cancer Institute
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Denver : Rocky Mountain Cancer Centers - Denver
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Denver : Rocky Mountain Cancer Center
A Study of MLN9708 in Adult Patients With Lymphoma
Denver :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Denver : Rocky Mountain Cancer Centers
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Denver : Rocky Mountain Blood and Marrow Transplant Program
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Denver : Colorado Blood Cancer Institute
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Denver : Denver Health Medical Center CACZ885M2301
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Denver : Investigational Site Number 840001
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Denver : Rocky Mountain Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Denver : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Denver : Rocky Mountain Cancer Centers
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Greenwood Village : Rocky Mountain Cancer Centers RMCC - Denver-Midtown
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Connecticut
Norwalk : Whittingham Cancer Center at Norwalk Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Southington : Cancer Center of Central Connecticut
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Danbury : Danbury Hospital Praxair Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Hartford : Hartford Hospital Cancer Clin Research Office
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
New Haven : Yale University, Site #033
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
New Haven : Yale Comprehensive Cancer Center at Yale University School of Medicine
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
New Haven : Yale University School of Medicine
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
New Haven : Yale Comprehensive Cancer Center at Yale University School of Medicine
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
New Haven : Yale University School of Medicine
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
Norwalk : Whittingham Cancer Center at Norwalk Hospital
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Norwalk :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Southington : Cancer Center of Central Connecticut
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Stamford : Hematology Oncology, P.C.
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
District of Columbia
Washington : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Washington : Pfizer Investigational Site
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Washington :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Washington :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Washington : George Washington University Department of Medicine
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
View More »
Washington : Georgetown University
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Washington : Washington Cancer Institute at Washington Hospital Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Washington : Georgetown University
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Washington : Georgetown Lombardi Comprehensive Cancer Center
Phase I Study of CS-7017 and Bexarotene
Washington : Georgetown University Hospital/Lombardi Cancer Center
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Florida
Ocala : Ocala Cancer Institute
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Altamonte Springs : Cancer Institute of Florida
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Aventura : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Boynton Beach : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Boynton Beach : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Boynton Beach : University Cancer Institute
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Boyton Beach : University Cancer Institute
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Coral Gables : University of Miami
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
Coral Springs : Coral Springs Oncology
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Daytona Beach : Halifax Health- Center for Oncology
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Englewood : Florida Cancer Specialist
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Fernandina Beach : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Fort Lauderdale : Holy Cross Hospital
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Fort Myers : Florida Cancer Specialists
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Ft. Myers : Florida Cancer Specialists North
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Gainesville : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Gainesville : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Gainsville : Florida Cancer Specialists & Research Institute
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Hollywood : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Hollywood : Alves/ Domenech Oncology-Hematology Clinic
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Jacksonville : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Jacksonville : Integrated Community Oncology Network-St. Vincent's
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Jacksonville : Integrated Community Oncology Network-Southside
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Jacksonville : Mayo Clinic
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Lake City : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lake Worth : Medical Specialists of the Palm Beaches
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Lecanto : Cancer and Blood Disease Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Loxahatchee : Hematology Oncology Associates
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Merritt Island : Space Coast Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Miami : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Miami : AMPM Research Clinic
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Miami : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Miami : Mercy Hospital
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Miami : Dr. Jorge Antunez de Mayolo office
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Miami : Dr. Luis Villa Private Office
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Miami : Mercy Research Institute
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Miami : University of Miami
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Miami : University of Miami
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Miami : Florida Academic Dermatology Center
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Miami : Florida Academic Dermatology Centers
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Miami : University of Miami Cancer Center
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Miami Beach : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
New Port Richey : Florida Cancer Institute ATI
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Orange Park : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Orange Park : Integrated Community Oncology Network
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Orange Park : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Orlando : MD Anderson Cancer Center Orlando
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Orlando : MD Anderson Cancer Center Orlando
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Orlando : Cancer Centers of Florida
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Orlando : Florida Hospital Cancer Institute
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Orlando : MD Anderson Orlando
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Orlando : MDACC Orlando
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Orlando : MD Anderson Cancer Center of Orlando
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Ormond Beach : Coastal Oncology, PL
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Pensacola : Investigational Site Number 840016
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Pensacola : Sacred Heart Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Pensacola : Woodlands Medical Specialists
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Port Lucie : Hematology Oncology Associates of Treasure Coast Hematology Onc of the Treasure
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Port St. Lucie : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Saint Petersburg :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Sarasota :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Sarasota :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Sarasota : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
St. Augustine : Integrated Community Oncology Network, LLC\CSNF: St. Augustine
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
St. Petersburg : Florida Cancer Specialists
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
St. Petersburgh : All Children's Hospital
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Tamarac : South Florida Oncology and Hematology Consultants
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Tampa : H. Lee Moffitt Cancer Center & Research Institute
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Tampa : H. Lee Moffitt Cancer Center & Research Institute
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Tampa : Moffitt Cancer Center
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Tampa : Moffit Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Tampa : Moffitt Cancer Center
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Tampa : H. Lee Moffitt Cancer Center
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Tampa : Moffitt Cancer Center & Research Institute
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Titusville : Space Coast Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Viera : Space Coast Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
West Palm Beach : Palm Beach Cancer Institute
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
West Palm Beach : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Winter Park : Hematology & Oncology Consultants, PA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Winter Park : Cancer Centers of Florida
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Georgia
Marietta : Northwest Georgia Oncology Centers PC
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Savannah : Memorial University Medical Center
ANHL04B1: Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma
Savannah : Memorial University Medical Center
SWOG S0806. A Phase I/II Trial of Vorinostat (SAHA)(NSC-701852) in Combination with Rituximab-CHOP in Patiens with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL).
View More »
Athens : Northeast Georgia Cancer Care
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Athens : Northeast Georgia Cancer Care
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Atlanta : Emory University Winship Cancer Institute
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Atlanta : Georgia Cancer Specialists - Admin Annex
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Atlanta : Emory Winship Cancer Institute
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Atlanta : Northside Hospital
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Atlanta : Emory University
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Atlanta : Emory University School Of Medicine
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Atlanta : Emory University Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Atlanta : Georgia Cancer Specialists
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Atlanta : Emory University Winship Cancer Institute
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Atlanta : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Atlanta : Investigational Site Number 840002
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Atlanta : Emory University
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Atlanta : Emory University
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Atlanta : Piedmont Hospital Cancer Center
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Atlanta : Georgia Cancer Specialists
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Atlanta : Winship Cancer Institute at Emory University
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Atlanta : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Atlanta : Children's Healthcare of Atlanta, Emory University
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Augusta : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Augusta : Investigational Site Number 840006
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Augusta : Medical College of Georgia
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Augusta : Georgia Health Sciences University
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Augusta : Investigational Site Number 840003
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Augusta : Investigational Site Number 840006
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Columbus : Columbus Regional
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Dublin : Dublin Hematology and Oncology
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Macon : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Marietta :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Marietta :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Marietta : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Riverdale : Southern Regional Medical Center
Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis
Roswell : Atlanta Cancer Care
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Savannah : Lewis Cancer Center and Research Pavilion
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Idaho
Boise : Investigational Site Number 840005
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Coeur D'alene :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Post Falls :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Post Falls : Kootenai Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Post Falls : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Illinois
Centralia : Southern Illinois Hematology Oncology
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Elgin : Sherman Health
ECOG E2408 A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Elgin : Sherman Health
S0816 - Phase II Intergroup A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Interim FDG-PET Imaging
Elgin : Sherman Health
SWOG S1106 Phase II Randomized Study of Induction Therapy Comprising Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Methotrexate, Cytarabine, and Leucovorin Calcium Versus Rituximab and Bendamustine Hydrochloride Followed by Consolidation Therapy and Autologous Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
Skokie : Clintell, Inc.
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Chicago : University of Chicago Medical Center, Site #001
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Chicago : Site Reference ID/Investigator# 71593
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chicago : Northwestern Memorial Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Chicago :
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Chicago : Northwestern University
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Chicago : University of Chicago Section of Hematology/Oncology Lymphoma Program
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Chicago : Children's Memorial Hospital
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Chicago : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Chicago :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Chicago :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Chicago : Rush University Medical Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Chicago : NorthwesternU
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Chicago : University of Chicago
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Chicago : Advocate Illinois Masonic Medical Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Chicago : Hematology Oncology Associates of Illinois
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Chicago : John H. Stroger, Jr. Hospital of Cook County
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Chicago : Northwestern University
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Chicago : Rush University Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Chicago : University of Chicago Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Chicago : UIC Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Chicago : Northwestern University
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Chicago : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Chicago : Rush University
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
Chicago : Rush University Medical Center Div. of Hematology & Oncology
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Chicago : Northwestern University Dept of Dermatology
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Chicago : Rush University
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Chicago : Univeristy of Chicago
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Chicago : Rush University Medical Center
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Chicago : Rush University Medical Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Danville : Carle Physician Group
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Decatur : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Decatur : Cancer Care Specialists of Central Illinois
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Effingham : Crossroads Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Galesburg :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Galesburg :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Harvey : Site Reference ID/Investigator# 67344
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Mattoon : Carle Foundation Physician Services
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Maywood : Investigational Site Number 840011
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Maywood : Loyola University Medical Center
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Maywood : Loyola University Medical Center /Cardinal Bernardin Cancer Loyola University (rm 101)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Maywood : Loyola University Medical Center, Cardinal Bernardin Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Maywood : Loyola Univeristy Medical Center, Cardinal Bernardin Cancer Center
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Niles : Illinois Cancer Specialists
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Niles : Illinois Cancer Specialists
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
Park Ridge : Oncology Specialists
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Peoria :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Peoria : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Skokie : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Skokie : North Shore Hematology Oncology
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Skokie : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Springfield : Simmons Cooper Cancer Institute at SIU School of Medicine
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Urbana : Carle Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Indiana
New Albany : Cancer Care Center Inc
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Bloomington : Cancer Care Center of Southern Indiana
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Fishers : Central Indiana Cancer Centers
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Fort Wayne : Fort Wayne Oncology & Hematology, Inc
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Goshen :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Goshen :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Goshen : Goshen Center for Cancer Care
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Indianapolis :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Indianapolis : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Indianapolis : IU Simon Cancer Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Indianapolis : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Indianapolis : St. Francis Medical Group Oncology and Hematology Specialists
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Indianapolis : Indiana University Simon Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Indianapolis : St. Francis Medical Group Oncology and Hematology Associates
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Indianapolis : Indiana Blood and Marrow Transplantation
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Indianapolis : Community Regional Cancer Center
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Indianapolis : IUPUI
Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Indianapolis : Indiana University Health Goshen Center for Cancer IU Cancer Center
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Indianapolis : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Indianapolis : Indiana University Simon Cancer Center
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Indianopolis : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Lafayette : Horizon Oncology Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Lafayette : Arnett Cancer Care
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Mishawaka : Northern Indiana Cancer Research Consortium St. Joseph Regional Medical Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
New Albany : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
New Albany : Floyd Memorial Cancer Center of Indiana
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
New Albany : Cancer Care Center Inc. P.C.
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
South Bend : Northern Indiana Cancer Research Consortium Memorial Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Terre Haute : RHHP/ Hope Cancer Center
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Terre Haute : RHHP/ Hope Cancer Center
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Iowa
Sioux City : Siouxland Hematology Oncology Associates
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Ames :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Cedar Rapids : Iowa Blood and Cancer Care
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Des Moines : Iowa Oncology Research Association
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Iowa City :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Iowa City : University of Iowa Hospitals & Clinics
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Iowa City : University of Iowa Hospitals and Clinics
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Iowa City : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Sioux City :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Sioux City : Siouxland Hematology and Oncology Associates LLP
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Kansas
Hutchinson : Hutchinson Clinic
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Kansas City : University of Kansas Medical Center
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
Kansas City : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Kansas City : Investigational Site Number 840010
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Kansas City : University of Kansas Medical Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Kansas City : University of Kansas Medical Center
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Overland Park : Kansas City Cancer Center, LLC
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Westwood : University of Kansas Medical Center, Westwood Campus
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
Westwood : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Westwood : Kansas University Medical Center
A Study of MLN9708 in Adult Patients With Lymphoma
Westwood :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Wichita : Cancer Center of Kansas
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Kentucky
Hazard : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lexington : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lexington : Investigational Site Number 840013
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Lexington :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Lexington : University of Kentucky
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
View More »
Lexington : Univ. of Kentucky Chandler Medical Center, Hematology/Oncology/BMT CRP, Markey Cancer Center
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Louisville :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Louisville :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Louisville : Baptist Hospital East
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Mt. Sterling : Montgomery Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Paducah :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Paducah : Investigational Site Number 840007
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Louisiana
Baton Rouge : Ochsner Clinic Baton Rouge
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Baton Rouge : Mary Bird Perkins Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Marrero :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Metairie :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
New Orleans : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
View More »
New Orleans : Tulane University Health Sciences Center Office of Clinical Research
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
New Orleans : Tulane
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Shreveport : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Shreveport : Louisiana State University Health Science Center (LSUHSC)
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Shreveport : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Maine
Portland :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Scarborough :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Scarborough : Maine Center for Cancer Medicine
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Maryland
Baltimore : Sinai Hospital of Baltimore
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
Baltimore : John Hopkins
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Baltimore :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Baltimore : Harry and Jeanette Weinberg Cancer Institute at Franklin Square
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Baltimore : University of Maryland
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
View More »
Baltimore : B. Douglas Smith, M.D.
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Baltimore : University of Maryland Greenebaum Cancer Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Baltimore : St. Agnes Hospital Dept.ofSt.AgnesHospital
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Baltimore : The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Baltimore : Johns Hopkins Medical Institutions
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Baltimore : Sidney Kimmel Comprehensive Cancer Center
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
Baltimore : The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
Baltimore : Sinai Hospital of Baltimore
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Baltimore : St. Agnes Hospital of Baltimore
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Baltimore : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Baltimore : Johns Hopkins University
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Baltimore : Johns Hopkins University
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Bethesda : Center for Cancer and Blood Disorders
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Bethesda : Center for Cancer & Blood Disorders, PC
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
Btk Inhibitor in Recurrent B Cell Lymphoma
Bethesda : Research Site
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Bethesda : Center for Cancer and Blood Disorders, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Bethesda : Center for Cancer and Blood Disorders
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Bethesda : Center for Cancer and Blood Disorders
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Bethesda : Center for Cancer & Blood Disorders
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Randallstown : Northwest Hospital Center
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
Silver Spring : Holy Cross Hospital
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Westminister : Saint Joseph's Medical Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Massachusetts
Boston : Dana-Farber Cancer Institute
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Boston : Massachusetts General Hospital Mass General
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Boston : Site Reference ID/Investigator# 48324
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Boston : Mass General Hospital (MGH), Site #047
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Boston : Dana-Farber Cancer Institute
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Boston : Boston University Medical Center
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Boston :
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Boston : Dana Farber Cancer Institute
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Boston : Dana Farber Cancer Institute
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Boston : Investigational Site Number 840004
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Boston : Investigational Site Number 840104
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Boston : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Boston :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Boston : Dana Farber Cancer Institute DFCI
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma
Boston : Dana-Farber Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Boston : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Boston : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Boston : Beth Israel Deaconess Medical Center
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Boston : Massachusetts General Hosptial
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Boston : Dana-Farber Cancer Institute
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Boston : Research Site
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Boston : Harvard Medical School-Mass General Hospital
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Boston : Boston Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Boston : Beth Israel Deaconess Medical Center
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Dana-Farber Cancer Institute
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Massachusetts General Hospital
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Dana Farber Cancer Institute
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Boston : Dana-Farber Cancer Institute
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Boston : Dana Farber Cancer Institute
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Boston : Dana-Farber Cancer Institute
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Boston : Massachusetts General Hospital
High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma
Boston : Dana Farber Cancer Institute
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Boston : Dana-Farber Cancer Institute
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Boston : Massachusetts General Hospital
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Boston : Dana-Farber Cancer Institute
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Boston : Massachusetts General Hospital
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Boston : Beth Israel Deaconess Medical Center
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Boston : Massachusetts General Hospital
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Boston : Dana Farber Cancer Institute
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Boston : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Boston : Massachusetts General Hospital
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Boston : Beth Israel Deaconess Medical Center
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Boston : Dana Farber Cancer Institute
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Boston : Dana Farber
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Boston : Dana-Farber Cancer Institute
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Burlington : Lahey Clinic Dept of Lahey Clinic (3)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Burlington : Lahey Clinic Medical Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Pittsfield : Berkshire Hematology Oncology, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Pittsfield : Berkshie Hematology Oncology
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Worcester :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Worcester : University of Massachusetts Medical School
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Worcester : University of Massachusets Memorial Medical Center
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Worcester : University of Massachusetts - Worcester
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Michigan
Ann Arbor : St. Joseph Mercy Hospital
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Ann Arbor :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Ann Arbor :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Ann Arbor : University of Michigan Cancer Center
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Ann Arbor : University of Michigan
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Ann Arbor : University of Michigan
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Ann Arbor : University of Michigan, Comprehensive Cancer Center
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Ann Arbor : University of Michigan
Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
Ann Arbor : C.S. Mott Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Dearborn : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Detriot : Henry Ford Health System
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Detroit :
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Detroit : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Detroit : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Detroit : Investigational Site Number 840001
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
Detroit :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Detroit : Karmanos Cancer Institute
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Detroit : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Detroit : Karmanos Cancer Institute
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Detroit : Karmanos Cancer Institute
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
Detroit : Barbara Ann Karmanos Cancer Institute
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
East Lansing : Michigan State University
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Farmington Hills : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Farmington Hills : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Flint : Genesys Hurley Cancer Institute
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Grand Rapids : Cancer & Hematology Center of Western Michigan
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Kalamazoo : West Michigan Cancer Center
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Kalamazoo : West Michigan Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Lambertville : ProMedica
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Lansing : Mid Michigan Physicians
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Minneapolis : University of Minnesota
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Novi : Detroit Clinical Research Center, PC
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Southfield : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Southfield : Newland Medical Associates
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Warren : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Minnesota
Rochester : Mayo Clinic
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Duluth : St. Luke's Hospital Cancer Care Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Duluth : Duluth Clinic
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Fridley : Metro Minnesota CCOP-Unity Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Maplewood : Metro Minnesota CCOP-St. Johns
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Minneapolis : Minnesota Oncology Hematology P.A.
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Minneapolis : Children's Hospital and Clinics of Minnesota
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Minneapolis : Novartis Investigative Site
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Minneapolis : University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Minneapolis : University of Minnesota Medical School
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Minneapolis : Childrens Hospital & Clinics of Minnesota
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Minneapolis : University of Minnesota Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Rochester : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Rochester : Mayo Clinic
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Rochester : Mayo Clinic
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Rochester : Mayo Clinic
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Rochester : Mayo Clinic
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Rochester : Mayo Clinic - Rochester Dept. of MayoClinic-Rochester
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Rochester : The Mayo Clinic
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Rochester : Mayo Clinic
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Rochester : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
St. Louis Park : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
St. Louis Park : Metro Minnesota Community Clinical Oncology Program
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
St. Louis Park : Metro Minnesota Community Clinical Oncology Program
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
St. Paul : Metro Minnesota CCOP-Regions Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Mississippi
Hattiesburg : Hattiesburg Clinic
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Jackson : University of Mississippi Medical Center
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Jackson : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
New Albany : The Jones Clinic, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Missouri
St. Joseph : St. Joseph Oncology Inc.
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Chesterfield : St. Louis Cancer Care
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Columbia : Missouri Cancer Associates
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Columbia : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Columbia : Missouri Cancer Associates
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Jefferson City :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Jefferson City :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Jefferson City : Columbia Comprehensive Cancer Care Clinic
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Kansas City : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Kansas City : Kansas City Cancer Center, LLC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Kansas City : Research Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Kansas City : Children's Mercy Hospital
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Kansas City : Saint Luke's Cancer Institute
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Saint Louis : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Saint Louis :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Saint Louis : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Saint Louis : Siteman Cancer Center at Washington University
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
St Louis : Investigational Site Number 840015
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
St Louis : Washington University
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
St. Louis : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
St. Louis : Washington University
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
St. Louis : Washington University School of Medicine
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
St. Louis :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
St. Louis : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
St. Louis : Pfizer Investigational Site
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
St. Louis : Washington University School of Medicine
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
St. Louis : Washington University School of Medicine Siteman Cancer Center Hematology Labs
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
St. Louis : St. Louis University Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
St. Louis : Washington University School of Medicine
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
St. Louis : Washington University
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
St. Louis : Washington University School Of Medicine-Siteman Cancer Ctr Div. of Medical Oncology
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
St. Louis : Washington University School of Medicine
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
St. Louis : Washington University Siteman Cancer Center
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
St. Louis : Washington University School of Medicine
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
St. Louis : Washington University
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
St.Louis : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Nebraska
Lincoln : Nebraska Hematology/Oncology
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
North Platte : Great Plains Regional Medical Center
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Grand Island : Saint Francis Medical Center
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Lincoln : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lincoln : Nebraska Hematology-Oncology, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Lincoln : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
North Platte : Great Plains Regional Medical Center
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Omaha : University of Nebraska Medical Center
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Omaha : University of Nebraska Medical Center
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Omaha : UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Omaha : University of Nebraska Medical Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Omaha : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Omaha : University of Nebraska Medical Center
Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
Omaha : University of Nebraska Medical Center
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Nevada
Henderson : Comprehensive Cancer Centers of Nevada
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Las Vegas : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Las Vegas : Comprehensive Cancer Centers of Nevada
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Las Vegas : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
New Hampshire
Lebanon : Dartmouth Hitchcock Medical Center
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Lebanon : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lebanon : Investigational Site Number 840017
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Lebanon : Dartmouth
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Lebanon : Dartmouth-Hitchcock Medical Center
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Lebanon : Dartmouth-Hitchcock Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Lebanon : Dartmouth Hitchcock Medical Center Dartmouth
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
New Jersey
Denville : Cancer Care at Saint Clare's/Saint Clares Hospital Oncology & Hematology Specialists, P.A.
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Hackensack : John Theurer Cancer Center (Hackensack University Medical Center)
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Hackensack : Hackensack University Medical Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Hackensack :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hackensack :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
View More »
Hackensack :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Hackensack : Hackensack University Medical Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Hackensack : Research Site
AMG 319 Lymphoid Malignancy FIH
Hackensack : Hackensack University Medical Center
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Hackensack : The Cancer Center at Hackensack University Medical Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Hackensack : John Theurer Cancer Center at Hackensack University Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Hackensack : Hackensack University Medical Center
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Hackensack : Hackensack University Medical Center
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Hackensack : Hackensack University Medical Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Hackensack : John Theurer Cancer Center
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
Hackensack : John Theurer Cancer Center at Hackensack University Medical Center
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Hackensack : Hackensack UMC / John Theurer Cancer Center
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Hackensack : John Theurer Cancer Center at Hackensack University
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Hackensack : Hackensack University Medical Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Hackensack : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Morristown :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Morristown : Hematology-Oncology Associates of North New Jersey
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Morristown : Hematology-Oncology Associates of Northern New Jersey
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Morristown : Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Morristown : Hematology-Oncology Associates of Northern NJ
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Morristown : Hematology/Oncology Associates of Northern New Jersey, P.A.
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Mount Holly :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Mount Holly : Virtua Health Cancer Program
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Mount Holly : Hematology Oncology Associates of South Jersey
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
New Brunswick : UMDNJ/Robert Wood Johnson
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
New Brunswick : Investigational Site Number 840002
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
New Brunswick : Cancer Institute of New Jersey
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
New Brunswick : Investigational Site Number 840001
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
New Brunswick : Cancer Institute of New Jersey
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Somerville : Somerset Hematology Oncology Associates
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Summit : Overlook Hospital and Morristown Memorial Hospital
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Vineland : South Jersey Health Care
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
New Mexico
Farmington :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Farmington :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
Phase 2 Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Multiple Myeloma Undergoing Limited Re-infusion of CD34+ Cells
New Hyde Park : CLL Research and Treatment Program
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
New Hyde Park : Biomedical Research Alliance of New York
Lymphoma
New Hyde Park : Biomedical Research Alliance of New York
Mantle Cell Lymphoma
New York : New York Presbyterian Hospital/Cornell Medical Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
New York : Columbia University
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
New York : Weill Medical College of Cornell University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.
New York : Georgetown University
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.
Rochester : Univ. of Rochester Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Valhalla : New York Medical College
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Albany : New York Oncology Hematology, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Bronx : Children's Hospital at Montefiore
A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer
Bronx : Montifiore Medical Center
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Buffalo :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Buffalo : Roswell Park Cancer Institute
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Buffalo : Roswell Park Cancer Institute
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Buffalo : Roswell Park Cancer Institute
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Buffalo : Roswell Park Cancer Institute
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Dunkirk :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
East Setauket : North Shore Hematology/Oncology Associates
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Fresh Meadows : Queens Medical Associates, Research
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Lake Success : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Long Island : Stony Brook
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
New Hyde Park : Site Reference ID/Investigator# 71813
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
New Hyde Park : CLL Research and Treatment Program
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
New Hyde Park : Long Island Jewish medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New Hyde Park : Long Island Jewish Medical Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
New York : Memorial Sloan Kettering Cancer Center MSK
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
New York : Site Reference ID/Investigator# 56810
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
New York : New York Presbyterian Hospital/ Cornell Medical Center
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
New York :
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
New York : Columbia University Medical Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
New York : Memorial Sloan Kettering Cancer Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
New York : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
New York : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
New York : Pfizer Investigational Site
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
New York :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
New York :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
New York : Weill Cornell Medical College
A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
New York : NYU Cancer Institute
A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred
New York : Memorial Sloan Kettering Cancer Center MSKCC (2)
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma
New York : Columbia University Medical Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
New York : Memorial Sloan-Kettering Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Weill Medical College of Cornell
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Memorial Sloan Kettering Cancer Center
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
New York : Memorial Sloan- Kettering Cancer Center
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
New York : Weill Cornell Medical College
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
New York : St. Luke's-Roosevelt Hospital Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
New York : Memorial Sloan Kettering Cancer Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
New York : Memorial Sloan-Kettering Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
New York : New York University Clinical Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
New York : Mount Sinai School of Medicine & Mount Sinai Graduate School of biological Sciences
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
New York : Columbia Presbyterian - Harlem
KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
New York : Columbia University Medical Center
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
New York : Weill Cornell Medical College
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
New York : New York Weill Cornell Cancer Center at Cornell University
Monoclonal Antibody hA20 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
New York : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
New York : Memorial Sloan-Kettering Cancer Center
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
New York : Memorial Sloan-Kettering Cancer Center
Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
New York : Weill Cornell Medical College
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
New York : Memorial Sloan Kettering Cancer Center
Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
New York : Weill Cornell Medical College
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
New York : Weill Cornell Medical College
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
New York : Memorial Sloan-Kettering
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
New York : Memorial Sloan-Kettering Cancer Center
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
New York : Memorial Sloan Kettering Cancer Center
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
New York : Mount Sinai School of Medicine
Safety and Efficacy Study of CAL-101 in Patients With Previously Treated Low-grade Lymphoma
New York : Memorial Sloan Kettering Cancer Ctr
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy
New York : Memorial Sloan-Kettering Cancer Center
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
New York : Weill Cornell Medical College
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
New York : Memorial Sloan - Kettering Cancer Center
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
New York : Memorial Sloan-Kettering Cancer Center
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
New York : Mount Sinai School of Medicine
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
New York : TG Therapeutics Investigational Trial Site
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
New York : Weill Med College of Cornell Univ/NYH
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
New York : Memorial Sloan-Kettering Cancer Center
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
New York : NYU Cancer Institute
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
New York : St. Luke's- Roosevelt Medical Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
New York : Cornell
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
New York : Memorial Sloan Kettering Cancer Center
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
New York : Weill Medical College of Cornell
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
New York : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
New York : Memorial Sloan Kettering Cancer Center
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
New York : Children's Hospital New York-Presbyterian
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
New York : Weill Cornell Medical College
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
New York City : Columbia Presbyterian Medical Center
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
New York City : Cornell University
A Study of MLN9708 in Adult Patients With Lymphoma
New York City : New York Hospital Weill Cornell Medical Center
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Rochester : Univ. of Rochester Cancer Center
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Rochester :
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Rochester : University of Rochester
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Rochester : University of Rochester Medical Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Rochester : University of Rochester Medical Center
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Rochester : University of Rochester Medical Center
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Rochester : University of Rochester
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Rochester : University of Rochester
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Rochester : University of Rochester School of Medicine
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Rochester : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Stony Brook : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Stony Brook : Stony Brook University Hospital
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Syracuse :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Syracuse : SUNY Upstate Medical Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Syracuse : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Valhalla : Investigational Site Number 840009
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
North Carolina
Boone : Seby B. Jones Cancer Center
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Cary : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Chapel Hill : University of North Carolina at Chapel Hill
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Chapel hill : University of North Carolina Chapel Hill
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Chapel Hill : University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
Induction Chemotherapy w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
View More »
Chapel Hill : Division of Hematology-Oncology, UNC Chapel Hill Lineberger Comprehensive Cancer Center
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Chaple Hill : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Charlotte :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Charlotte : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Charlotte : Levine Cancer Institute Oncology
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Charlotte : Levine Children's Hospital at Carolinas Medical Center
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Concord : Northeast Medical Center
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Concord : Carolinas Medical Center Northeast
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Durham : Site Reference ID/Investigator# 71393
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Durham : Research Site
AMG 319 Lymphoid Malignancy FIH
Durham : Duke University Medical Center
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Durham : Duke University Medical Center
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Durham : Duke University Medical Center
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Durham : Duke University Medical Center
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Durham : Duke University Medical Center
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Durham : Duke University Medical Center
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Durham : Duke University
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Durham : Duke University Medical Center
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Fayetteville : Carolina Cancer Management, Inc.
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Greensboro : Moses Cone Regional Cancer Center
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Greensboro : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Greenville : Leo Jenkins Cancer Center, East Carolina University Medical Center
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
High Point :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Raleigh : Rex Healthcare
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Raleigh : Raleigh Hematology Oncology Associates P.C.
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Washington : Marion L. Shepard Cancer Center
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Winston-salem :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Winston-Salem : Wake Forest University Baptist Medical Center Dept. of WFUHS
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Winston-Salem : Wake Forest University Health
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
North Dakota
Bismarck :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Fargo : Roger Maris Cancer Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Ohio
Columbus : The Ohio State University
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Akron : Summa Health System
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Canton : Investigational Site Number 840014
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Canton : Gabrail Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Cincinnati :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Cincinnati : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Cincinnati : Cincinnati Children's Hospital Medical Center
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Cincinnati : Oncology Hematology Care
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Cleveland : Cleveland Clinic, The
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Cleveland : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Cleveland : Cleveland Clinic
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Cleveland : Case Comprehensive Cancer Center - University Hospitals Case Medical Center
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Cleveland : Seidman Cancer Center
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Cleveland : Cleveland Clinic Taussig Cancer Center
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Cleveland : Cleveland Clinic
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
Cleveland : Case Western Reserve University, University Hospitals of Cleveland
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cleveland : Cleveland Clinic, Taussig Cancer Institute
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cleveland : Cleveland Clinic
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Cleveland : University Hospitals-Case Medical Center
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Columbus : The Ohio State University
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Columbus : The Ohio State University Medical Center
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Columbus : The Ohio State University Comprehensive Cancer Center
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Columbus :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Columbus : The Ohio State University Medical Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Columbus : Ohio State University Medical Center
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Columbus : Mid Ohio Oncology/Hemagology Inc. dba The Mark H. Zangmeister Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Columbus : Riverside Methodist Hospital Riverside Cancer Services
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Columbus : Ohio State University
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Columbus : Ohio State University Medical Center
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Columbus : The Ohio State University - Comprehensive Cancer Center
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
Columbus : Ohio State University Medical Center
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Columbus : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Columbus : Nationwide Childrens Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Columbus : Ohio State University Comprehensive Cancer Center
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Columbus : Ohio State University
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Dayton : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Dayton : Dayton Clinical Oncology Program
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Dayton : Dayton Physicians, LLC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Dover : Gabrail Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Elyria : Mercy Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Kettering : Dayton Physicians, LLC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Lorain : Community Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Middletown :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Newark : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sylvania : ProMedica Health System, Inc.
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Toledo : Mercy St. Vincent Medical Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Toledo : Mercy Cancer Center at St. Anne's
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Toledo : Toledo Clinic Cancer Center-Toledo
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Toledo : Toledo Clinical Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
West Chester : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Oklahoma
Norman : Mercy Physicians of Oklahoma
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Oklahoma City : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY3023414 in Participants With Advanced Cancer
Oklahoma City : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Oklahoma City : Mercy Physicians of Oklahoma
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Oregon
Clackamas : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Corvallis : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Eugene : Willamette Valley Cancer and Research / USOR
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Eugene : Willamette Valley Cancer and Research / USOR
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Eugene :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
View More »
Eugene : Willamette Valley Cancer Institute and Research Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Eugene : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Newport : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Portland : Oregon Health & Sciences
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Portland : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Portland :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Portland :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Portland : Oregon Health & Science University
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Portland : Northwest Cancer Specialists, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Portland : OHSU Knight Cancer Institute
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL
Portland : Kaiser Group Health
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Portland : Oregon Health Sciences University
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Springfield :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Springfield : Willamette Valley Cancer Institute and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Springfield : Willamette Valley Cancer Institute and Research Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Springfield : US Oncology Research: Willamette Valley Cancer Institute and Research Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Springfield : Willamette Valley Cancer Institute and Research Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Tualatin : Northwest Cancer Specialists, P.C.
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Tualatin : Northwest Cancer Specialists, P.C.
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Tualatin : Northwest Cancer Specialists, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Pennsylvania
Philadelphia : University of Pennsylvania, Abramson Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Philadelphia : Temple University
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Pittsburgh : Western Pennsylvania Cancer Institute
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Pittsburgh : Allegheny General Hospital
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Dunmore : Hematology and Oncology Associates of NEPA
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Hazleton : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Hershey : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Hershey : Penn State Hershey Cancer Institute
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Hershey : Penn State University / Milton S. Hershey Medical Center Dept.ofMiltonS.HersheyMedCtr.
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Philadelphia : Fox Chase Cancer Center Fox Chase Cancer (2)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Philadelphia : University of Pennsylvania, Site #013
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Philadelphia : University of Pennsylvania, Abramson Cancer Center
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Philadelphia : Investigational Site Number 840001
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Philadelphia : Thomas Jefferson University
A Study of MLN9708 in Adult Patients With Lymphoma
Philadelphia : Thomas Jefferson University
Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas
Philadelphia : Thomas Jefferson University
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Philadelphia : Fox Chase Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Philadelphia : Pennsylvania Oncology Hematology Associates
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Philadelphia : Fox Chase Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Philadelphia : Fox Chase Cancer Center
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Philadelphia : Abramson Cancer Center, University of Pennsylvania
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
Philadelphia : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Pittsburgh : University of Pittsburgh
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Pittsburgh : Children's Hospital of Pittsburgh
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Pittsburgh : UPMC Hillman Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Pittsburgh : University of Pittsburgh Medical Center SC-3
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Pittsburgh : University of Pittsburgh School of Medicine
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Pittsburgh : University of Pittsburgh
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Pittsburgh : UPMC Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Sayre : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Sayre : Guthrie Clinic, Ltd
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Sayre : Guthrie Clinic
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
W Reading : Berks Hematology Oncology Associates
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
W. Reading : Reading Hospital Regional Cancer Center
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Willow Grove : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
York : Cancer Care Associates of York
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
York : York Cancer Center / Cancer Care Associates of York
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Rhode Island
East Providence : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Providence : Rhode Island Hospital
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Providence : Rhode Island Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Providence : The Miriam Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
South Carolina
Charleston :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Charleston : Charleston Hematology Oncology Associates, PA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Charleston : Medical University of South Carolina
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Charleston : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Charleston : Medical University of South Carolina MUSC/HCC (2)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
View More »
Charleston : Investigational Site Number 840002
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Columbia :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Columbia : South Carolina Oncology Associates, PA
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Greenville : Saint Francis Hospital
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Greenville : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Greenville : Upstate Oncology Associates
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Greenville : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Greenville : Saint Francis Hospital
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Greenville : Cancer Centers of the Carolinas
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Hardeeville : South Carolina Cancer Specialists
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Hilton Head Island : South Carolina Cancer Specialists
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
South Dakota
Sioux Falls : Avera Cancer Institute
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Rapid City : Rapid City Regional Hospital John T. Vucurevich Cancer Care Institute
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Sioux Falls : Avera Hematology and Transplant
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Watertown :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Tennessee
Nashville : Vanderbilt-lngram
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Chattanooga : Chattanooga Oncology Hematology Associates
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Chattanooga : Chattanooga Oncology and Hematology Associates, PC
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Germantown : The Jones Clinic, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Kingsport : Kingsport Hematology Oncology
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Knoxville : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Maryville : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Memphis : Research Site
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Memphis : University of Tennessee Cancer Institute
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Memphis : The West Clinic
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Memphis : University of Tennessee Cancer Institute SC-2
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Memphis : St. Jude
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Nashville : Vanderbilt-Ingram
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Nashville :
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Nashville :
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Nashville :
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Nashville : Sarah Cannon Research Institute
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Nashville :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Nashville :
A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY3023414 in Participants With Advanced Cancer
Nashville :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Nashville : Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2)
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma
Nashville : Sarah Cannon Research Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Nashville : Sarah Cannon Cancer Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Nashville : Vanderbilt University Medical Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Nashville : Sarah Cannon Research Institute
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Nashville : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Nashville : SCRI
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Nashville : Tennessee Oncology, PLLC
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Nashville : Sarah Cannon Cancer Center at Centennial Medical Center
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
Nashville : Sarah Cannon Research Institute
Safety and PK Study of RRx-001 in Cancer Subjects
Nashville : Vanderbilt
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Nashville : Sarah Cannon Research Institute Tennessee Oncology Drug Development Unit
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Nashville : Vanderbilt -Ingram Cancer Center
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Nashville : Sarah Cannon Research Institute (SCRI) Drug Development Unit
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
Nashville : Sarah Cannon Research Institute (SCRI)
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Nashville : Tennessee Oncology
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Nashville : Sarah Cannon Research Institute
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Nashville : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Nashville : Vanderbilt Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Sevierville : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Texas
Houston : MD Anderson Cancer Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Richardson : HOPE Oncology
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Austin : Texas Oncology Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Dallas : Baylor University Medical Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Dallas : Mary Crowley Cancer Research Centers - Medical City
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Dallas : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Dallas : Investigational Site Number 840003
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
Dallas : Baylor Sammons Cancer Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Dallas : UT Southwestern
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Dallas : Mary Crowley Cancer Research Centers
Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Dallas : University of Texas Southwestern Medical Center
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Dallas : Mary Crowley Cancer Research Centers
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Dickinson : UTMB Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Fort Sam Houston : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Fort Worth : Texas Oncology-Southwest Fort Worth
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Fort Worth : Center for Cancer and Blood Disorders
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Fort Worth : JPS Center for Cancer Care
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Fort Worth : The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Fort Worth : US Oncology- Central Drug
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Fort Worth : US Oncology- Central Laboratory
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Galveston : University of Texas Medical Branch at Galveston
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Houston : UT MD Anderson Cancer Center
5-Azacytidine and Oxaliplatin With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
Houston : Site Reference ID/Investigator# 48326
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Houston : MD Anderson Cancer Center
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Houston : MD Anderson Cancer Center
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Houston :
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Houston : MD Anderson Cancer Center / University of Texas
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Houston : Texas Children's Hospital
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Houston :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Houston : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Houston :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Houston : UT MD Anderson Cancer Center
A Study of the HSP90 Inhibitor AUY922
Houston : The University of Texas MD Anderson Cancer Center
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Houston :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Houston :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Houston : UT MD Anderson Cancer Center
Acupuncture for Chemo-Induced Peripheral Neuropathy
Houston : MD Anderson Cancer Center
A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases
Houston : Methodist Hospital
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Houston : MD Anderson Cancer and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : MD Anderson Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : UT MD Anderson Cancer Center
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Houston : UT MD Anderson Cancer Center
Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies
Houston : M D Anderson Cancer Center
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Houston : UT MD Anderson Cancer Center
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Houston : UT MD Anderson Cancer Center
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)
Houston : MD Anderson Cancer Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Houston : University of Texas MD Anderson Cancer Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Houston : UT MD Anderson Cancer Center
Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies
Houston : UT MD Anderson Cancer Center
Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma
Houston : The Methodist Cancer Center
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Houston : U.T. M.D. Anderson Cancer Center
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Houston : UT MD Anderson Cancer Center
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Houston : MD Anderson Cancer Center
Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
Houston : UT MD Andreson Cancer Center
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Houston : MD Anderson Cancer Center
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
Houston : UT MD Anderson Cancer Center
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma
Houston : Baylor College of Medicine Dept.of Baylor College of Med.
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Houston : MD Anderson Cancer Center/University of Texas Dept of MD Anderson (18)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Houston : UT MD Anderson Cancer Center
Pomalidomide for Relapse/Refractory Waldenstrom's
Houston : MD Anderson Cancer Center
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Houston : UT MD Anderson Cancer Center
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Houston : MD Anderson Cancer Center - Dept. of Lymphoma and Myeloma
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
Houston : Texas Children's Hospital
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
Houston : MD Anderson Cancer Center
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Houston : UT MD Anderson Cancer Center
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
Houston : UT MD Anderson Cancer Center
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Houston : UT MD Anderson Cancer Center
Stem Cell Collection With Ofatumumab
Houston : Investigational Site Number 840003
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Houston : MD Anderson Cancer Center
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Houston : MD Anderson Cancer Insititute
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Houston : UT MD Anderson Cancer Center
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Houston : Oncology Consultants P.A.
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Houston : The University Of Texas Md Anderson Cancer Center
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Houston : MD Anderson Cancer
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Houston : MD Anderson Cancer Center
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Houston : MD Anderson Cancer Center
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Laredo : South Texas Research Alliance, LLC
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Lubbock : Joe Arrington Cancer Research and Treatment Center
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Lubbock : Joe Arrington Cancer Research and Treatment Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
McAllen : Texas Oncology
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
New Braunfels : Cancer Care Centers of South Texas-HOAST
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Plano : Leading Edge Research, PA
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Round Rock : Texas Oncology - Seton Williamson
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
San Antonio : South Texas Accelerated Research Therapeutics
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
San Antonio :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
San Antonio :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
San Antonio : Cancer Care Centers of South Texas-HOAST
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
San Antonio : South Texas Oncology and Hematology, P.A.
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
San Antonio : University of Texas Health Science Center, San Antonio
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
San Antonio : University of Texas Health Science Center at San Antonio
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
San Antonio : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
San Antonio : South Texas Accelerated Research Therapeutics (START)
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
San Antonio : South Texas Oncology and Hematology, PA South Texas Oncology (2)
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
San Antonio : South Texas Accelerated Research Therapeutics, LLC
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
San Antonio : South Texas Accelerated Research Therapeutics, LLC (START)
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
San Antonio : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Temple : Scott and White Hospital and Clinic
A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases
Temple : Texas A&M HealthSciencesCtr-Scott & White Memorial Hospital CenterForCancerPrevention&Care
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
The Woodlands : US Oncology- Central Regulatory
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Tyler : Texas Oncology - Tyler
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Tyler :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Tyler : Tyler Hematology Oncology, PA
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Tyler : Tyler Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Waco : Texas Oncology
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Waco : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Weslaco : Texas Oncology
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Wichita Falls : Texoma Cancer Center
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Utah
Ogden : Northern Utah Associates
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Bountiful : Lakeview Hospital Campus
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Layton : Davis Hospital Campus
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Murray : Intermountain Medical Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Provo : Utah Valley Regional Medical Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Salt Lake City : Huntsman Cancer Institute
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Salt Lake City : Salt Lake Regional Medical Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Salt Lake City : Utah Cancer Specialists Cancer Center
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Salt Lake City : Salt Lake Clinic
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Salt Lake City : University of Utah
Phase 1 Pharmacokinetics Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Salt Lake City : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Salt Lake City : Huntsman Cancer Institute At the University of Utah
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
West Jordan : Utah Cancer Specialists-Jordan Valley Campus
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Vermont
Burlington :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Burlington : Fletcher Allen Health Care
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Burlington : University of Vermont Office of Clinical Trials Res.
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Virginia
Charlottesville : Virginia University
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Charlottesville : Virginia University
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Charlottesville : University of Virginia Health System
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Charlottesville : University of Virginia Health System
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients
Charlottesville : University of Virginia Health System
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Charlottesville : University of Virginia Health Systems Div. of Hematology/Oncology
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Charlottesville : Research Site
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
Fairfax :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Falls Church : Inova Fairfax Medical Center
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Richmond :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Richmond : Virginia Cancer Institute
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Richmond : Massey Cancer Center/Virginia Commonwealth University
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Richmond : Virginia Cancer Institute
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Roanoke :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Roanoke :
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Roanoke : Blue Ridge Cancer Care
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Roanoke : Blue Ridge Research Center at Roanoke Neurological Center SC
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Washington
Seattle : Fred Hutchinson Cancer Research Center
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
Tacoma : MultiCare Health System
A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Tacoma : MultiCare Health System
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
View More »
Edmonds : Puget Sound Cancer Centers
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Edmonds : Puget Sound Cancer Centers
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Federal Way : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Gig Harbor : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Lakewood : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Puyallup : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Seattle : Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research SC
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Seattle : Site Reference ID/Investigator# 52882
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Seattle : Fred Hutchinson Cancer Research Center
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Seattle : Seattle Cancer Care Alliance / University of Washington Medical Center
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Seattle :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Seattle : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Seattle : Pfizer Investigational Site
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Seattle :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Seattle : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Seattle : Seattle Cancer Care Alliance
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Seattle : University Of Washington
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Seattle : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Seattle : Fred Hutchinson Cancer Research Center
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Seattle : Fred Hutchinson Cancer Research Center
Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
Seattle : Seattle Cancer Care Alliance
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Seattle : Seattle Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Seattle : Virginia Mason
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Seattle : Swedish Cancer Institute
Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Spokane : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Tacoma : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Vancouver :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Vancouver : Northwest Cancer Specialists, PC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Vancouver : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Vancover : Northwest Cancer Specialists PC
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients
Walla Walla : St Mary Medical Center/Regional Cancer Center
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Wenatchee : Wenatchee Valley Medical Center
A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Yakima :
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma
Yakima : Yakima Regional Cancer Care
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Yakima : Yakima Valley Memorial Hospital/North Star Lodge
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Yakima : GSK Investigational Site
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Yakima : North Star Lodge Cancer Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
West Virginia
Huntington : Marshall University
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
Morgantown : West Virginia University - Clinical Trials Research Unit
BMTCTN-0701: Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Remission
Morgantown : West Virginia University - Clinical Trials Research Unit
C50604 - Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin's Lymphoma
Morgantown : West Virginia University - Clinical Trials Research Unit
ECOG 2408: A Three-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenolidomide/Rituxan in High Risk Follicular Lymphoma
Morgantown : West Virginia University - Clinical Trials Research Unit
OMB110918-A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment
Morgantown : West Virginia University - Clinical Trials Research Unit
S0816 - A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin's Lymphoma Using Early Interim FDG-PET Imaging
View More »
Morgantown : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Morgantown : Investigational Site Number 840002
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Morgantown :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Morgantown : Mary Babb Randolph Cancer Center
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Morgantown : West Virginia University
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Morgantown : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Morgantown : West Virginia University, WVU Healthcare
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Morgantown : West Virginia University Mary Babb Randolf Cancer Center
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Wisconsin
Madison : University of Wisconsin Madison
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.
Marshfield : Marshfield Clinic
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma
View More »
Green Bay : Green Bay Oncology-St. Mary's Hospital MC
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Green Bay : Saint Vincent Hospital Green Bay Oncology
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Green Bay : Bellin Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Green Bay : St Vincent Regional Cancer Center
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Green Bay : Aurora Baycare Medical Center-GreenBay
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Green Bay : Bellin Memorial Hospital, Inc
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Janesville : Mercy Health System Heme/Onc
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
LaCrosse : Gundersen Clinic
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
LaCrosse : Gunderson Lutheran Health System
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Madison : Site Reference ID/Investigator# 56811
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Madison : University of Wisconsin Madison
A Study of MLN9708 in Adult Patients With Lymphoma
Madison :
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Madison :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Madison : University of Wisconsin
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Madison : University of Wisconsin Comprehensive Cancer Center
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Madison : Dean Health System
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Madison : University of Wisconsin Carbone Cancer Center
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Madison : University of Wisconsin
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Madison : University Of Wisconsin Cancer Center
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Madison : UW Health Oncology- 1 S Park
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Marinette : Aurora BayCare Medical Center
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Marshfield : Marshfield Clinic
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Marshfield : Marshfield Clinic
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Milwaukee : Children's Hospital of Wisconsin
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Milwaukee : Medical College of Wisconsin
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Milwaukee : Medical College of Wisconsin
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Milwaukee : Columbia St Mary's, Inc
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Oconomowoc : Oconomowoc Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Sheboygan : Aurora Sheboygan Memorial Medical Center
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Summit : Aurora Medical Center in Summit
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Two Rivers : Aurora Medical Center in Two Rivers
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Waukesha : Waukesha Memorial Hospital Cancer Center Dept.ofWaukeshaMemorialHosp.
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Waukesha : Waukesha Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Waukesha : Waukesha Memorial Hospital
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Wauwatosa : Aurora Health Care Metro, Inc.
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Wisconsin Rapids : Riverview Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Wisconsin Rapids : UW Cancer Center-Riverview
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Albania
Tirana :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Argentina
Buenos Aires : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Ciudad Autonoma de Buenos Aires : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Cordoba : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
La Plata : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Australia
Nedlands : Sir Charles Gairdner Hospital
A Phase 3 study of PCI-32765 (ibrutinib) versus ofatumumab in patients with relapsed or refractory chronic lymphocyctic leukemia (CLL) and small lymphocytic lymphoma (SLL) - "RESONATE"
View More »
Adelaide :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Adelaide : Royal Adelaide Hospital
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Adelaide : Royal Adelaide Hospital
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Adelaide : Royal Adelaide Hospital
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Brisbane : Princess Alexandra Hospital
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
Clayton : Investigational Site Number 036002
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Clayton : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Concord : Concord Repatriation General Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Douglas : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
East Melbourne : Site Reference ID/Investigator# 48323
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
East Melbourne : Site Reference ID/Investigator# 70394
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
East Melbourne : Peter MacCallum Cancer Centre
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
East Melbourne :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
East Melbourne : Pfizer Investigational Site
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
East Melbourne : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Fitzroy : St. Vincent's Hospital
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Fitzroy :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Frankston :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Geelong : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Greenslopes : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Herston :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Herston : Royal Brisbaine and Womens Hospital
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Hobart : Investigational Site Number 036001
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Kogarah : St George Hospital/
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Malvern : Cabrini Health
Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Melbourn : The Alfred Hospital
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Melbourne : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Melbourne : Peter MacCallum Cancer Centre
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Melbourne :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Nedlands : Sir Charles Gairdner Hospital
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Nedlands : Sir Charles Gairdner Hospital
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Nedlands : Sir Charles Gairdner Hospital and University of Western Australia
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Parkville : Site Reference ID/Investigator# 48322
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Parkville : Site Reference ID/Investigator# 70393
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Perth : Investigational Site Number 036003
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Perth :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Perth :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
St. Leonards : Royal North Shore Hospital
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sydney :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Westmead, NSW : Children's Hospital at Westmead
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Woodville South : The Queen Elizabeth Hospital
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Woolloongabba : Princess Alexandra Hospital
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Woolloongabba : Princess Alexandra Hospital
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Austria
Graz :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Graz : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Innsbruck :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Innsbruck : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Innsbruck : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
View More »
Leoben : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Linz : Krankenhaus der Barmherzigen
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Linz :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Linz : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Linz : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Rankweil :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Salzburg : Center for Clinical Cancer and Immunology Trials
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Vienna : Medical University of Viena
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Vienna : Wilhelminenspital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : AKH Vienna
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : Hanusch Krankenhaus
Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)
Wels : Abteilung für Innere Medizin IV
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Wien : Wilhelminenspital
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Wien :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Wien : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Belarus
Brest : Brest Oncology Center Updated
Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
Gomel : Gomel Oncology Center Updated
Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
Grodno : Grodno Regional Hospital Updated
Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
Vitebsk : Vitebsk Medical State University Updated
Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
Belgium
Aalst :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Antwerpen : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Brugge :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Brugge : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Brugge : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
View More »
Brussels : Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet
CREATE: Cross-tumoral Phase 2 With Crizotinib
Brussels : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Brussels : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Bruxelles : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Bruxelles : Investigational Site Number 056003
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Bruxelles :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Bruxelles : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Bruxelles : Institut Jules Bordet
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
Charleroi : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Edegem :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Gent : Investigational Site Number 056002
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Gent :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Gent : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Gent : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Gent : Investigational Site Number 056002
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Gent : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Gent :
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Kortrijk :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Kortrijk : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Leuven : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Leuven : UZ Leuven
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Leuven : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Leuven : Investigational Site Number 056001
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Leuven : U.Z. Gasthuisberg
CREATE: Cross-tumoral Phase 2 With Crizotinib
Leuven : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Leuven : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Leuven : Investigational Site Number 056001
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Leuven : University Hospitals Leuven
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
Liège :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Lueven : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Mons : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Roeselare : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Verviers :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Wilrijk : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Wilrijk :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Wilrijk : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Yvoir : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Yvoir : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Bosnia and Herzegovina
Banja Luka :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Sarajevo :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Brazil
Belo Horizonte :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Campinas : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Curitiba : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Curitiba : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Florianopolis :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
View More »
Jau : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Porto Alegre :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Porto Alegre : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Rio de Janeiro : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Rio de Janeiro : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Sao Paulo :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Sao Paulo :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
São Paulo : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Bulgaria
Pleven :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Pleven :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Plovdiv : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Plovdiv : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Plovdiv : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
View More »
Sofia :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Sofia : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Sofia : Tokuda Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Sofia : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Varna : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Canada
Montreal, Quebec : Jewish General Hospital
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.
View More »
Barrie : Royal Victoria Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Barrie : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Brampton : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Calgary : Tom Baker Cancer Centre
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Calgary : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Calgary : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Calgary : Alberta Children's Hospital
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Cambridge : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
East York :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Edmonton : Cross Cancer Institute
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Edmonton :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Edmonton : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Edmonton :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Edmonton : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Greenfield Park : Charles LeMoyne Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Greenfield Park : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Halifax : Queen Elizabeth II Health Sciences Centre
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma
Halifax : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Halifax : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Halifax, : Queen Elizabeth II, Health Services Centre
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Hamilton : Juravinski Cancer Centre at Hamilton Health Sciences
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Hamilton : McMasters University Medical Center
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Hamilton : Juravinski Cancer Centre
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Kelowna :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
London : London Health Sciences Centre
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Mississauga : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Moncton :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Moncton : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Montreal : McGill University - Dept. Oncology
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Montreal : Jewish General Hospital
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma
Montreal : Sacré-Cœur Hospital
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma
Montreal :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Montreal : Jewish General Hospital
A Study of MLN9708 in Adult Patients With Lymphoma
Montreal :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Montreal :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Montreal : McGill University Heath Centre-Department of Oncology
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Montreal : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Montreal : Hopital Maisonneuve-Rosemont
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
Ottawa : Ottawa Hospital General Campus
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Ottawa : Ottawa Hospital-General Campus
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Ottawa : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Québec : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Québec : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Quebec City :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Regina : Allan Blair Cancer Centre
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Sainte-Foy : Quebec Children's Hospital
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Saskatoon : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Sherbrooke : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Sherbrooke :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
St. Catherine : Hospital St. Justine
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
St. John's : General Hospital Division of Hematology Oncology
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Sudbury : Hôpital régional de Sudbury Regional Hospital
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Toronto : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Toronto : Univ. Health Network-Princess Margaret Hospital
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Toronto : Princess Margaret Hospital
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma
Toronto : Sick Children's Hospital
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Toronto : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Toronto : Princess Margaret Hospital
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Toronto : Sunnybrook Health Sciences Centre, Odette Cancer Centre
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Toronto : Research Site
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Toronto : Princess Margaret Hospital
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg
Toronto : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Toronto : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Toronto : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Toronto : Hospital for Sick Kids
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Vancouver : BC Cancer Agency-Vancouver Centre
A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas
Vancouver : British Columbia Cancer Agency - Vancouver Centre
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma
Vancouver :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Vancouver :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Vancouver :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Vancouver : Gordon and Leslie Diamond Health Care Centre Hematology Administration
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Vancouver : BC Cancer Agency
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
Windsor :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Winnepeg : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Winnipeg : Cancer Care Manitoba
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
China
Beijing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Beijing :
A Study of RO5072759 (GA101) in Patients With CD20+-Malignant Lymphoma
Beijing : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Beijing : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Beijing : Teva Investigational Site 01
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
View More »
Beijing : Teva Investigational Site 02
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Beijing : Teva Investigational Site 03
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Beijing : Teva Investigational Site 04
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Beijing : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Beijing : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Beijing : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Changchun : Teva Investigational Site 15
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Changsha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Changzhou City :
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Chengdu : Teva Investigational Site 10
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Chengdu : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Fuzhou :
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Guang Zhou : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
Guangzhou :
A Study of RO5072759 (GA101) in Patients With CD20+-Malignant Lymphoma
Guangzhou : Pfizer Investigational Site
An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Guangzhou : Teva Investigational Site 07
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Guangzhou : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Guangzhou, Guangdong Province : Teva Investigational Site 08
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Hangzhou : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Hangzhou, , Zhejiang : Teva Investigational Site 11
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Hong Kong : Department of Paediatrics and Adolescent Medicine, The University of Hong Kong
A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Jiang Su Province : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Jinan :
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Liaoning Province : Teva Investigational Site 09
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Nanjing, Jiangsu Province : Teva Investigational Site 13
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Nanjing,Jiangsu Province : Teva Investigational Site 12
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Shanghai :
A Study of RO5072759 (GA101) in Patients With CD20+-Malignant Lymphoma
Shanghai : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Shanghai : Teva Investigational Site 05
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Shanghai : Teva Investigational Site 06
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Shanghai : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Shanghai : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Tianjin :
A Study of RO5072759 (GA101) in Patients With CD20+-Malignant Lymphoma
Tianjin : Teva Investigational Site 14
Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment
Tianjin : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Tianjin : Tianjin Medical University Cancer Institute and Hospital
Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma
Xi'an :
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Colombia
Bogota :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Bogota :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Bogotá : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Medellin :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Medellin :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
View More »
Medellín : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Pereira :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Croatia
Zagreb : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Czech Republic
Bratislava : Dr Ludmila Demitrovicova
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
Brno : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Brno :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Brno :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Brno : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
View More »
Brno : Investigational Site Number 203002
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Brno : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Brno - Bohunice : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Brno-Bohunice : FN Brno
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Hradec Kralove :
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Hradec Kralove :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hradec Kralove :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Hradec Kralove : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Hradec Kralove : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Hradec Kralove : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Hradec Králové : Fakultni nemocnice Hradec Kralove
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Hradec Kralove 5 : University Hospital Hradec Kralove
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Olomouc : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Prague :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Praha : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Praha : Charles University General Hospital
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Praha : Charles University
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Praha 10 : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Praha 10 : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Praha 10 : Investigational Site Number 203003
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Praha 2 :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Praha 2 : Investigational Site Number 203001
SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients
Praha 2 : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Znojmo : Nemocnice Znojmo
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Denmark
Aarhus : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Aarhus : Aarhus University Hospital
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Århus :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Copenhagen : Rigshospitalet, Department of Hematology
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Koebenhavn : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
View More »
Odense :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Vejle :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Ecuador
Guayaquil :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Egypt
Alexandria : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Cairo :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Cairo : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Mansoura : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Estonia
Tallinn : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Finland
Helsinki :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Helsinki :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
Helsinki : Helsinki University Central Hospital
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.
Helsinki : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Oulu : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
View More »
Tampere : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Turku :
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
France
Amiens cedex1 : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Angers :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Angers :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Argenteuil : CH Victor Dupouy
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Avignon Cedex : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
View More »
Besancon :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Besancon cedex : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Bobigny : Hopital Avicenne
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Bordeaux : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Bordeaux : Service d'Hematologie - Institut Bergonié
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Bordeaux :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Bordeaux :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Brest :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Brest : Service Hématologie, Hôpital Augustin Morvan
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Brest : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Brest Cedex 2 : ICH CHU Brest- C.H.U. MORAVAN
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Caen :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Cedex : CHU Côte de Nacre
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Clermont : Service d'Hematolgie Clinique - CHU Estaing
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Clermont-Ferrand : Service Hématologie et Thérapie cellulaire, Pavillon Villemin Pasteur, CHU Clermont-Ferrand
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Clermont-Ferrand : CHU Clermont-Ferrand, Hôpital d'Estaing
Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
Clermont-Ferrand : CHU de Clermont-Ferrand
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Clermont-ferrand Cedex 1 : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Clermont-Ferrand Cedex 1 : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Corbeil-essonnes :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974 AM1)
Creteil :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Creteil :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Creteil :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Creteil : Novartis Investigative Site
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Creteil Cedex : Investigational Site Number 250004
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dijon :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Dijon :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Dijon :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Dijon : Investigational Site Number 250009
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dijon : CHU de Dijon
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
Grenoble : Hôpital Michallon
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Grenoble : CHU de Grenoble-Hopital Albert Michallon
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Grenoble : Valerie ROLLAND NEYRET
Study of Mantle Cell Lymphoma Treatment by RiBVD
La Roche Sur Yon :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
La Roche Sur Yon : Chd -Vendee
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
La Roche sur Yon cedex 9 : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
La Roche sur Yon Cedex 9 : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
La Tronche :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Le Chesnay :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Le Chesnay Cedex : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Le Mans : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Le Mans : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Lemans :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Lille : CHU Claude Huriez
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Lille :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Lille :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Lille : CHRU- Hôpital Claude Huriez
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Lille : CHRU Lille
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Lille : CHRU - Hopital Claude HURIEZ
Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL
Lille Cedex :
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Lille Cedex : Investigational Site Number 250006
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Lille Cedex : Novartis Investigative Site
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Limoges :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Limoges cedex : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Lyon : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Lyon :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Lyon : Centre Leon Berard
Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
Lyon : Centre hospitalier Lyon Sud
Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL
Lyon : Hôpital Edouard Herriot
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Lyon : Centre Hospitalier Lyon Sud
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Lyon Cedex : Novartis Investigative Site
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma
Marseille : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Marseille :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Marseille : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Marseille Cedex 9 : Investigational Site Number 250011
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Marseille Cedex 9 : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Marseille Cedex 9 : Local Institution
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Marsielle : Institute Paoli-Calmette
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Metz :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Montpellier :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Montpellier :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Montpellier : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Montpellier : Investigational Site Number 250002
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Montpellier :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Montpellier :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Montpellier : Montpellier University Hospital
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Montpellier : Investigational Site Number 250010
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Montpellier : CHU St Eloi
Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL
Montpellier cedex 5 : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Mulhouse :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Mulhouse N/A :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Nantes :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Nantes :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Nantes : CHU de Nantes - Hôtel Dieu
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
Nantes Cedex : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Nantes Cedex 01 : Investigational Site Number 250006
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Nantes Cedex 01 : Investigational Site Number 250008
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Nantes Cedex 1 : Hotel Dieu
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Nantes Cedex 1, : CHRU - Hotel Dieu, Hématologie
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Nantes N/A :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Nantes-Saint Herblain : Centre René Gauducheau
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
Nice :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Nice Cedex 1 : Centre Antoine Lacassagne
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Paris :
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Paris :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Paris :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Paris :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Paris : APHP Hôpital Henri-Mondor
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Paris : APHP Hôpital Pitié-Salpêtrière
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Paris : APHP Hôpital Saint Louis
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Paris : Pfizer Investigational Site
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Paris Cedex 10 : Investigational Site Number 250007
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Paris Cedex 10 : Local Institution
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Paris Cedex 12 : Hopital D'Enfants Armand-Trousseau
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Pessac : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Pessac : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Pessac :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Pessac :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Pessac : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Pessac : CHRU-Hopital du Haut -Leveque
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Pessac Cedex : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Pessac cedex : GSK Investigational Site
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Pierre Benite :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Pierre Benite :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Pierre Benite :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Pierre Benite : Hospices Civils de Lyon
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Pierre Benite Cedex : Investigational Site Number 250001
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Pierre Benite Cedex : Investigational Site Number 250001
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pierre-Benite Cédex : Novartis Investigative Site
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Poitiers :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Poitiers :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Rennes : Investigational Site Number 250004
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Rennes : Service Hématologie Clinique, Hôpital Pontchaillou
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Rennes : Rennes EFS
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Rennes : Rennes University Hospital
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Rennes : Investigational Site Number 250005
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Rennes : CHU Rennes
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Rennes : CHU de Rennes Hopital de Pontchaillou
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Rennes Cedex : CHU de Rennes Hôpital de Pontchaillou
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
RENNES cedex 9 : Pfizer Investigational Site
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Rouen : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Rouen :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Rouen :
A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Rouen : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Rouen : Centre Henri Becquerel
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Rouen : Centre de Lutte contre le Cancer Henri Becquerel
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Rouen Cedex : Investigational Site Number 250005
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Rouen Cedex : Investigational Site Number 250003
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Rouen Cedex 1 : Novartis Investigative Site
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Saint Cloud : Centre René Huguenin
Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients
Saint Etienne : Institut de Cancérologie de la Loire
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
Saint Priest en Jarez Cedex : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
St Priest en Jarez : Institut de Cancerologie de la Loire
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Strasbourg :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Toulouse : University Hospital OF Toulouse Purpan
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Toulouse Cedex : Institut Claudius Régaud
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Tours : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tours :
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Vandoeuvre : Nancy University Hospital - Hôpitaux de Brabois
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Vandoeuvre :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Vandoeuvre Les Nancy :
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
Vandoeuvre les Nancy : CHU de Nancy
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Vandoeuvre-les Nancy cedex : Hopital de Brabois Adultes
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Villejuif :
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Villejuif :
A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Villejuif :
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Villejuif : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of LY3039478 in Participants With Advanced Cancer
Villejuif :
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma
Villejuif : Institut Gustave-Roussy
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
Villejuif Cedex : Investigational Site Number 250003
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Villejuif Cedex : Novartis Investigative Site
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma
Villejuif Cedex : Investigational Site Number 250002
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Villejuif Cedex : Institut Gustave Roussy, Dept. of Medicine
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Georgia
Tbilisi :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Germany
Aachen : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Aachen : Klinik fuer Onkologie und Haematologie, Medizinische Klinik IV
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Aachen : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Amberg :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Aschaffenburg : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
View More »
Augsburg : Childrens's Hospital, Pediatric Oncology and Hematology
Vorinostat in Children
Bamberg : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Bamberg : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Berlin : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Berlin : MediOnko-Institut GRR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : "Medizinisches Versorgungszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Fachärzte für Innere Medizin - Hämatologie u. Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Onkoplan GmbH/ Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Berlin : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Berlin : Novartis Investigative Site
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Berlin : Charité Campus Virchow Klinikum Klinik für Pädiatrie m.S. Onkologie/Hämatologie
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Berlin : Charité Campus Benjamin Franklin
Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Bochum :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Bonn : "Praxiskooperation Bonn-Euskirchen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Bonn : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Borken : "Facharzt für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Brandenburg : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Bremen : Prof. Hess Childrens's Hospital, Pediatric Oncology and Hematology
Vorinostat in Children
Chemnitz : Poliklinik GmbH Chemnitz
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Cottbus : Fachärztin für Innere Medizin / Hämatologie / Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Darmstadt :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Darmstadt :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Dortmund :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Dresden :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Dresden :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Dresden : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Dresden : "Facharzt für Innere Medizin/
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Dresden : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Eisenach : "Facharzt für Innere Medizin Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Essen : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Essen : Universitätsklinikum Essen
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Essen : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Essen : Universitätsklinikum Essen
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies
Essen : University Childrens's Hospital, Pediatric Oncology and Hematology
Vorinostat in Children
Frankenthal : Internist / Hämatologe / Intern. Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Frankfurt : Research Site
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Frankfurt :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Frankfurt : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Frankfurt Am Main : Investigational Site Number 276003
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Frankfurt am Main : 1270.2.49004 Boehringer Ingelheim Investigational Site
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Frankfurt/Main : Local Institution
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Frechen :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Freiburg :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Freiburg : Universitätsklinikum Freiburg - Medizinische Klinik
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Freiburg : Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg (KTB)
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies
Freiburg : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Freiburg : University Children's Hospital, Clinic IV
Vorinostat in Children
Garbsen : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
GIEßEN :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Goch : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Gosiar : Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Göttingen : UKG Universitätsklinikum Göttingen
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Göttingen : 1270.2.49003 Boehringer Ingelheim Investigational Site
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Göttingen : Prof. Trümper
Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma
Göttingen : Universitäts-Krebszentrum Göttingen - CCC
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Greifswald :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Greifswald :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Groitzsch : Medizinisches Studien- und Dokumentationszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Halberstadt : FA für Innere Medizin - Hämatologie - Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Halle :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Halle : Universitätsklinikum Halle Klinik und Poliklinik für Kinder- und Jugendmedizin
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Hamburg :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Hamburg : 1270.2.49001 Boehringer Ingelheim Investigational Site
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Hamburg : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Hamburg : Department of Pediatric Oncology and Hematology University Hospital Eppendorf (UKE)
Vorinostat in Children
Hannover : MediProjekt Ges. f. Medizinstatistik und Projektentwicklung
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover : University Children's Hospital, Pediatric Oncology and Hematology, MHH
Vorinostat in Children
Heidelberg : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Heidelberg :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Heidelberg : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Heidelberg : 1270.2.49002 Boehringer Ingelheim Investigational Site
BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Heidelberg : Clinic for Pediatric Oncology, Hematology, Immunology and Clinical Cooperation Unit Pediatric Oncology
Vorinostat in Children
Heidenheim : ODZ-Petersen GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Herne : DOKUSAN Gesellschaft für medizinische Studien mbH & Co. KG
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Herrsching : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
HOF :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Homburg : Universitätsklinikum des Saarlandes
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Homburg/saar :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Jena :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Jena : Investigational Site Number 276002
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Jena : "Medizinisches Versorgungszentrum MP Saaletal GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Jena : Pfizer Investigational Site
Registry for Temsirolimus and Sunitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Jena : University Childrens's Hospital, Pediatric Oncology and Hematology
Vorinostat in Children
Kaiserslautern :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Kaiserslautern : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Karlsruhe :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Karlsruhe : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Kassel : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Kiel : Klinik für Dermatologie, Venerologie und Allergologie
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Kiel :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Kiel : Universitätsklinikum Schleswig Holstein
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Koblenz : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Koeln : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Koln : University Hosptial Cologne
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Köln : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Köln :
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Köln :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Köln : University Children's Hospital, Pediatric Oncology and Hematology
Vorinostat in Children
Krefeld : OnkoMed GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Landshut :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Landshut : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Lebach :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Lehrte :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Leipzig :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Lübeck :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Ludwigshafen :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Magdeburg :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Magedburg :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Magedburg :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Mainz : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Mainz : Klinikum der Johannes-Gutenberg Universität
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Mainz : Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Mainz : Universitätsmedizin
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Mainz : Universitätsmedizin Mainz
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Mannheim :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Mannheim : UniversitaetsMedizin Mannheim
CREATE: Cross-tumoral Phase 2 With Crizotinib
Marburg :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Marburg :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Marburg : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Mayen :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Muenchen :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Muenchen :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Muenchen :
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Muenchen : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Muenchen : Klinikum Grosshadern Ludwig-Maximilians Univ. Muenchen
CREATE: Cross-tumoral Phase 2 With Crizotinib
Muenchen : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Muenchen : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Muenchen : Novartis Investigative Site
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Munchen : Facharzle fur Innere Medizin - Hamatologie u. Intemistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munchen : Facharzte fur Innere Medizin - Hamatologie u. Intermistische Onkologie - Bluttransfusionswesen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
München :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
München :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
München :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Munster : Gemeinschaftspraxis für Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Münster :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Münster : Department of Pediatric Oncology and Hematology University Children's Hospital
Vorinostat in Children
Naunhof :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Neuss : Tumorzentrum Niederrhein GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Überörtliche Gemeinschaftspraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Facharzt für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Olpe :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Olpe : Medizinisches Versorgungszentrum Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oranienburg : Fachärztin für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Osnabruck : Paracelsusklinik
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Paradiese : Medizinisches Versorgungszentrum GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : FA f. Innere Medizin, Onkologie und Endokrinologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Plauen : FA für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Recklinghausen :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Recklinghausen : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Regensburg :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Regensburg :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Remscheid : Facharzt für Innere Medizin - Medikamentöse Tumortheraphie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rodgau : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rostock :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Saarbruecken :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Saarbruecken :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Schoenebeck : FA fur Innere Medizin - Hamatologie - Intermistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Singen :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Stralsund : "FA f. Frauenheilkunde und Geburtshilfe SP Gynakologische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Stuttgart :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Stuttgart :
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Ulm : Novartis Investigative Site
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Ulm : Pfizer Investigational Site
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Ulm : Investigational Site Number 276001
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Ulm : Universitätsklinikum Ulm
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Ulm : Universitätsklinikum
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Ulm : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Velbert : Praxis fur Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Verden : Facharzt für Innere Medizin Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
VS-Villingen : Onkologische Schwerpunktpraxis Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Weilheim : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Wiesbaden : Pfizer Investigational Site
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Würzburg :
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Würzburg : University Hospital Würzburg
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Würzburg : Universititätsklinikum
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Greece
Alexandroupolis : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Athens :
A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera
Athens :
A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma
Athens :
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
Athens : GSK Investigational Site
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
View More »
Athens : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Haidari, Athens : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Heraklion Crete : Novartis Investigative Site
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Heraklion, Crete : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Ioannina : GSK Investigational Site
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
